President and Chief Executive Officer · ARS Pharmaceuticals, Inc. (SPRY)

Richard Lowenthal

A named executive officer of ARS Pharmaceuticals in every fiscal year CompBrief holds from FY2022 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$9,656,400

FY2024: $7,174,995

1st of 3 named executive officers at ARS Pharmaceuticals by FY2025 total.

3 named officers on file for ARS Pharmaceuticals, FY2025

See an example →

What this number hides

The filing gives the total. ARS Pharmaceuticals’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 29, 2026 (DEF 14A).

Free

Get Richard Lowenthal’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Richard Lowenthal and every company like it: Velarion Intel, free for 3 days, no card →

Richard Lowenthal compensation by year

ARS Pharmaceuticals Summary Compensation Table · all 4 fiscal years held
In US dollars, as ARS Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024FY2025
Salary$74,630$620,000$651,000$700,000
Bonus$100,000$0$0—
Stock awards$0$0$0—
Option awards$0$7,293,000$3,842,080$6,176,110
Non-equity incentive$188,076$260,400$507,780$315,000
Pension and deferred compensation$0$0$0—
All other$113,642$1,865,696$2,174,135$2,465,290
Total$476,343$10,039,096$7,174,995$9,656,400

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARS Pharmaceuticals, Inc. DEF 14A filed April 29, 2026, accession 0001193125-26-191433, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ARS Pharmaceuticals, Inc. filed document, accession 0001193125-26-191433. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.

$476K
$10.0M
$7.2M
$9.7M
FY22
FY23
FY24
FY25
SalaryBonusNon-equity incentiveOption awardsAll other

ARS Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Richard Lowenthal · this pagePresident and Chief Executive Officer$9,656,400
Sarina TanimotoChief Medical Officer$5,290,471
Justin ChakmaChief Business Officer$2,888,109

The full ARS Pharmaceuticals compensation record

free company brief

This page is one person within ARS Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ARS Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ARS Pharmaceuticals's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARS Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order SPRY

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Richard Lowenthal's compensation dossier